Company intelligence / Profile preview

LifeSplice Pharma

Malvern, Pennsylvania, United Stateslifesplicepharma.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 2

Overview

LifeSplice Pharma has demonstrated preclinical proof-of-concept for its SMO-based therapies. Lead candidates have shown efficacy in animal models of Dravet Syndrome and ALS, including reduced mortality and delayed disease progression.

Therapeutic areas: Neurology
Modalities: Splice Modulating Oligomers (SMOs)RNA-based therapeutics
Industry: Biotech

Drug pipeline

3 assets

LSP-GR3

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

NIH SBIR Fast Track CREATE grant recipient; no major pharma partnerships disclosed yet

Beyond the preview

Go deeper on LifeSplice Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LifeSplice Pharma.

Explore the full profile